The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISAL 2019 | Christoph Röllig on AML research in Dresden, Germany
Christoph Röllig, MD, MSc, discusses the ongoing research into acute myeloid leukemia (AML) at his insitute, Dresden University of Technology, Dresden, Germany. He highlights the coordination of clinical trials, treatment sites and registries. Dr Röllig also discusses the DaunoDouble trial (NCT02140242), with further results expected to be presented at ASH 2019. This interview took place at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.
